What is RKTO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RKTO?

P/E (TTM) is n/a and 52-week range is $0.47 to $2.45 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RKTO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RKTO?

The company profile lists net income (TTM) near -$21M, EPS (TTM) near -$0.83 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Rocket One Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Hoboken, New Jersey, US, 24.9M shares outstanding, ISIN US44148G2049 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Rocket One Inc

$RKTO

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Rocket One, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in Hoboken, New Jersey and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic artificial intelligence (AI) chip technology designed for radiation-tolerant, energy-constrained environments such as low-earth orbit, deep-space platforms, and defense systems. The company operates through two segments, which include Biopharmaceutical and AI semiconductor infrastructure. The company is also focused on a nanomagnetic matrix multiplier, Skyrmion Spintronic memory, and Swarm Stage AI. The firm's biotechnology pipeline includes HT-001, HT-KIT, HT-ALZ, and its glial cell line derived neurotrophic factor (GDNF)-based metabolic program. The HT-001 is used to treat epidermal growth factor receptor (EGFR)-induced skin disorders. The HT-KIT drug is used to treat the receptor tyrosine kinase KIT in mast cells.

Employees

Website

hoththerapeutics.com

IPO

2019-02-15

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US44148G2049

Headquarters

Hoboken, New Jersey, US

Shares outstanding

24.9M

NAICS sector

Manufacturing

Institutional ownership

6.50%

Browse other companiesFree AI scores and summaries for more stocks